Skip to main content

Nuclear Receptors as Drug Targets

Nuclear Receptors as Drug Targets

Eckhard Ottow (Editor), Hilmar Weinmann (Editor), Raimund Mannhold (Series Editor), Hugo Kubinyi (Series Editor), Gerd Folkers (Series Editor)

ISBN: 978-3-527-62329-7

Dec 2008

522 pages


Edited by two experts working at the pioneering pharmaceutical company and major global player in hormone-derived drugs, this handbook and reference systematically treats the drug development aspects of all human nuclear receptors, including recently characterized receptors such as PPAR, FXR and LXR. Authors from leading pharmaceutical companies around the world present examples and real-life data from their own work.
Nuclear Receptors as Modern Drug Targets - a Historic Perspective
Targeting the Nuclear Receptor -
Cofactor Interaction
Untangling the Estrogen Receptor Web
Subtype Selective Estrogens
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Progesterone Receptor and Progestines
Progesterone Receptor Antagonists
Nonsteroidal Tissue Selective Androgen Receptor Modulators
The Glucocorticoid Receptor as Target for Classic and Novel Anti-inflammatory Therapy and Novel Glucocorticoid Receptor Ligands
Vitamin D Analogs as Modulators of Vitamin D Receptor Action
PPARs: Therapeutic Targets for Metabolic Disease and Type 2 Diabetes
Retinoids in Clinical Use
Nuclear Receptors as Targets in Cardiovascular Diseases
NURR77 Family of Nuclear Receptors and its Modulators
Induction of Drug Metabolism: The Role of Nuclear Receptors
Nuclear Receptor Targeted Screening Libraries and Chemogenomics Approaches
""With increasing importance attributed to this area, the text is a welcome review of the current field.... The quality of the text is good with very readable chapters and many useful original literature references. The book will be clearly valuable for both academic and industrial groups engaged in drug discovery."" (Journal of Medicinal Chemistry, March 2009)

""This is an excellent book for scientists interested in adding or expanding expertise in nuclear receptor drug discovery to their skill set. The chapters are timely, well referenced into the 2008 literature, and focused on the chemistry of successful and emerging therapeutic small molecules."" (Journal of the American Chemical Society, March 10, 2009)

""The book is a good reference for medicinal chemists, pharmacologists and those working in the pharmaceutical industry."" (RoSearch, December 2008)